Is There a Shot for Seasonal Allergies?

Allergy shots do exist, and they remain the most established injection-based treatment for seasonal allergies. Formally called subcutaneous immunotherapy (SCIT), these shots involve repeated injections of tiny amounts of the allergens that trigger your symptoms, gradually retraining your immune system to tolerate them. Unlike antihistamines or nasal sprays that mask symptoms, allergy shots are the only widely available treatment that can change the underlying disease process. But “a shot for seasonal allergies” can mean several things depending on context, and the options, timelines, and trade-offs vary more than most people realize.

What Allergy Shots Actually Are

Allergy shots are a form of allergen immunotherapy that has been in use for over a century. The classical protocol, introduced in 1911, involves repeated subcutaneous injections of increasing amounts of allergen extract, followed by maintenance injections over a period of about three years. The goal is to achieve a form of allergen-specific tolerance that provides clinical benefit for years after the shots are discontinued.¹ They are given in a doctor’s office, and you typically wait 30 minutes afterward so staff can watch for reactions.

Allergen immunotherapy stands apart from every other allergy treatment because it is the only disease-modifying option available.² Antihistamines, decongestants, and steroid nasal sprays all suppress symptoms while you use them. Stop taking them, and the symptoms come right back. Allergy shots aim to change how your immune system responds to the allergen itself, so the relief can persist long after you stop treatment.

How the Immune System Gets Retrained

When you have seasonal allergies, your immune system overreacts to harmless substances like pollen by producing IgE antibodies. Those antibodies sit on the surface of mast cells, and when pollen lands on them, the mast cells dump histamine and other chemicals that cause sneezing, itching, and congestion. Allergy shots work by shifting this response. Over time, your body starts producing a different type of antibody, IgG4, which acts as a blocking antibody. It intercepts the allergen before it can latch onto the IgE sitting on mast cells, preventing the allergic cascade from firing.³

The shift goes deeper than just antibody swapping. Allergy shots promote regulatory T cells that actively suppress the overblown allergic response. These cells dial down the activity of the immune players responsible for allergic inflammation, including mast cells, eosinophils, and basophils, and they do it through anti-inflammatory signaling molecules.⁴ The result is a broad dampening of the allergic response rather than a single-target fix, which is part of why the benefits tend to last.

The Two-Phase Treatment Timeline

Allergy shots follow a two-phase schedule. In the buildup phase, you receive injections one to two times per week, with gradually increasing doses of allergen extract. Under a standard protocol, reaching the target maintenance dose takes about 31 weeks. Once you hit maintenance, injections drop to roughly once a month and continue for about three years total.⁵

That timeline is a dealbreaker for some people. Driving to a clinic once or twice a week for months, then monthly for years, is a serious commitment. One study found a dropout rate of about 12% before three years, with the most common reasons being other medical problems, difficulty keeping up with appointments, moving, inconvenience, and allergic reactions to the shots themselves.⁶ That 12% figure may actually understate the problem in broader practice, since it came from a motivated patient population at a specialty clinic.

Faster Ways to Reach Maintenance

If you cannot stomach months of weekly visits, accelerated protocols exist. Cluster schedules give multiple injections per visit, spaced apart by about 30 minutes, so you can compress the buildup phase. Rush protocols go even faster, sometimes reaching maintenance dose in a single day or a few days. In a comparison of the three approaches, cluster protocols reached maintenance in about 19 weeks and rush protocols in about 17 weeks, compared with 31 weeks for standard buildup. The rate of systemic reactions was statistically similar across all three, hovering around 10 to 15 percent regardless of speed.⁵

Rush protocols do typically involve pretreatment with antihistamines or corticosteroids to reduce the chance of a reaction. They are not offered everywhere and are generally reserved for patients who are well-selected by an allergist and can be closely monitored during the procedure.

How Well Do They Work, and How Long Does the Benefit Last?

The evidence for allergy shots in seasonal allergic rhinitis is strong. Symptom reduction tends to begin during the buildup phase and grows progressively. The longer the treatment continues, the greater the benefit, and the effects persist for years after you stop.⁷ Most guidelines recommend three years of maintenance injections to maximize the chance of lasting tolerance. Some patients maintain symptom control for a decade or more after completing treatment, though individual responses vary.

It is worth noting that much of the strongest efficacy data comes from European studies using single-allergen extract vaccines, which differ from the multi-allergen mixes commonly used in the United States.⁸ European regulatory standards have generally pushed toward standardized single-allergen products, while American allergists often treat with customized mixes targeting several allergens at once. Both approaches are used clinically, but the evidence base is not perfectly symmetric between them.

Beyond symptom relief, allergy shots appear to slow the progression of allergic disease. In children with allergic rhinitis, immunotherapy may reduce the risk of developing asthma and prevent new allergen sensitivities from emerging, a concept sometimes called arresting the “allergic march.”⁹ That preventive angle is one of the strongest arguments for starting immunotherapy in younger patients rather than managing symptoms indefinitely with medications.

Safety and What Can Go Wrong

You are being injected with something your immune system is already primed to overreact to, so reactions are inherently possible. Most are local: redness, swelling, or itching at the injection site. Systemic reactions, meaning symptoms beyond the injection site like hives, wheezing, or drops in blood pressure, occur in roughly 2% of patients receiving allergy shots. Severe reactions (grade 3 and 4) are uncommon, affecting about 0.1% of patients or fewer.¹⁰

Fatal anaphylaxis from allergy shots is extremely rare but not zero. That risk is the reason you sit in the clinic for 30 minutes after each injection and why these shots cannot be self-administered at home. Physicians need to be prepared with epinephrine and resuscitation equipment.¹¹ Known risk factors for serious reactions include uncontrolled asthma and dosing errors, which is why a careful assessment before starting treatment matters.

Sublingual Tablets as an Alternative to Injections

If needles or frequent clinic visits are the sticking point, sublingual immunotherapy (SLIT) offers another route. Instead of injections, you dissolve a tablet or drops under your tongue daily at home. SLIT targets the same immune retraining process as shots. A comparison of the two approaches found that sublingual treatment was effective in controlling nasal allergy symptoms with or without asthma, reduced medication use, improved lung function measures, and appeared comparable to subcutaneous injections in overall effectiveness.¹²

In the United States, FDA-approved sublingual tablets currently cover a limited set of allergens: certain grass pollens, ragweed, and dust mites. If your primary triggers fall outside those categories, SLIT tablets are not yet an option in the U.S. market, though custom sublingual drops are used off-label by some allergists. SLIT’s biggest practical advantage is convenience. Its biggest limitation is the narrow menu of approved allergens compared with the flexible, customizable mixes used in injection therapy.

Biologic Injections That Target IgE Directly

There is another type of shot that takes a fundamentally different approach. Omalizumab is a biologic medication, originally developed for moderate-to-severe asthma, that directly blocks IgE from binding to mast cells. Rather than gradually teaching your immune system to tolerate an allergen, it yanks IgE out of the equation entirely for as long as you keep getting injections. In a randomized controlled trial, patients with seasonal allergic rhinitis who received omalizumab experienced reduced symptoms compared with placebo, with the greatest benefit seen in those with moderate to severe disease and clear IgE-mediated sensitivity.¹³

Intriguingly, even a single preseasonal injection of omalizumab, given two weeks before pollen season alongside standard medications, was shown to decrease the need for rescue medications and provide better eye symptom control and quality-of-life improvements compared with standard therapy alone.¹⁴ That is a very different proposition from three years of allergy shots. The catch is cost: omalizumab is expensive, and insurance coverage for seasonal rhinitis alone (as opposed to asthma) can be difficult to obtain. It is typically reserved for people whose allergies are severe and inadequately controlled by other treatments.

What About Steroid Shots?

Many people asking about “a shot for allergies” are thinking of a corticosteroid injection, sometimes called a “Kenalog shot” or “allergy steroid shot.” These are single intramuscular injections of a long-acting steroid that suppresses inflammation system-wide for weeks. They can provide dramatic short-term relief, and some primary care clinics have historically offered them at the start of allergy season.

The medical community has largely moved away from recommending them for seasonal allergies. One study comparing a steroid nasal spray with an allergen injection course found that the nasal spray group had minimal symptoms and used very little rescue medication, while a substantial number of subjects in the injection group had to withdraw due to severe rhinitis or reactions to the injections.¹⁵ Beyond efficacy concerns, systemic steroid injections carry risks of blood sugar spikes, bone density loss, weight gain, and adrenal suppression that topical nasal steroids mostly avoid. For a condition that recurs every year, repeated systemic steroid injections add up to a worrying cumulative exposure. Most allergists now recommend steroid nasal sprays as a far safer way to achieve steroid-based symptom control.

Who Is a Good Candidate for Allergy Shots?

Not everyone with seasonal sniffles needs immunotherapy. The general path is: try avoidance strategies and over-the-counter medications first. If those do not provide adequate relief, or if the medications cause side effects you dislike, or if you have been relying on medication for years and want a more permanent solution, allergy shots become worth discussing.

A proper allergy workup is essential before starting. A positive skin prick test or blood test shows only that your immune system has produced IgE antibodies to a specific allergen, a state called sensitization. It does not automatically mean that allergen is causing your symptoms. An allergist needs to match your clinical history with the test results before designing a treatment plan.¹⁶ This step matters because immunotherapy is only effective against the specific allergens included in your formulation. If the wrong allergens are chosen, you go through years of injections for nothing.

People with uncontrolled asthma, certain heart conditions, or those taking beta-blockers need extra caution. Beta-blockers can interfere with the treatment of anaphylaxis, making even a rare severe reaction harder to manage. Children are often good candidates because of the potential to prevent disease progression, though very young children may not tolerate the injection schedule well.

Cost and Whether the Investment Pays Off

Allergy shots are not cheap upfront. Between the extract costs, office visit copays for weekly and then monthly injections, and the time investment of three-plus years, the total expense adds up. However, analyses of the broader economics consistently find that immunotherapy is cost-effective when measured against the long-term burden of allergic disease, factoring in reduced medication costs, fewer doctor visits, and improved quality of life.¹⁷ The break-even point is usually a few years after completing treatment, once you stop paying for injections but are still enjoying the benefits.

Insurance coverage varies. Most major U.S. insurers cover allergy shots, but copays per visit can range from nominal to frustrating. SLIT tablets are sometimes covered but less consistently. Omalizumab, when approved for rhinitis-related use, is often the most expensive option. If you are weighing costs, the relevant comparison is not just the sticker price of allergy shots versus a bottle of antihistamines. It is the cumulative cost of decades of daily medication, multiple specialist visits, and missed work or school days against a finite course of treatment that may eliminate the problem.

Lengthening Pollen Seasons and the Growing Case for Immunotherapy

Climate change is reshaping the allergy landscape in ways that make disease-modifying treatments increasingly relevant. Rising temperatures are extending pollen seasons, increasing pollen counts, and even making pollen grains more allergenic. Exposure to higher levels of carbon dioxide, ozone, and diesel exhaust particles amplifies the allergic potency of pollen and fungal spores. The geographic distribution of allergenic plants is shifting, meaning people in regions that historically had low pollen burdens are encountering new triggers.¹⁸

For someone who already struggles through a two-month pollen season, the prospect of that season stretching to three or four months strengthens the argument for a treatment that addresses the root cause. Allergists are being urged to adapt both diagnostic and treatment strategies to account for these environmental shifts.

What Is Coming Next

Current allergy shots work, but the field recognizes they are slow, require many clinic visits, and carry a nonzero risk of serious reactions. Research is moving toward next-generation approaches that aim to fix these limitations. Advances in molecular biology have enabled new vaccine strategies including recombinant allergens (lab-made versions of the proteins that trigger allergies), hypoallergenic derivatives (modified versions designed to train the immune system with less risk of reactions), allergen-derived peptides, and even nucleic acid-based vaccines.¹⁹ The shared goal is a treatment that is safer, faster, and more precise, ideally requiring fewer doses while still delivering lasting tolerance. None of these have replaced conventional allergy shots yet, but several are in clinical trials, and the pace of development has picked up considerably in the last decade.